Biologics Market
Report ID: SQMIG35H2127
Report ID: SQMIG35H2127
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35H2127 |
Region:
Global |
Published Date: August, 2025
Pages:
194
|Tables:
155
|Figures:
78
Global Biologics Market size was valued at USD 567.54 Billion in 2024 and is poised to grow from USD 629.97 Billion in 2025 to USD 1451.79 Billion by 2033, growing at a CAGR of 11% during the forecast period (2026–2033).
There is a greater need for sophisticated diagnostics and potent treatment drugs because chronic diseases like diabetes, rheumatoid arthritis, and cancer are more prevalent and simpler to diagnose. This has aided in the global biologics market growth. The treatment of autoimmune and inflammatory diseases has relied heavily on biologics, which are genetically modified medications intended to target elements of the immune system. The need for robust healthcare systems has been further highlighted by the COVID-19 pandemic, which has led some countries to strengthen their supply chains and invest in biological research. To improve the yield and quality of biology, researchers are also actively investigating a variety of species and expression systems.
Additionally, oral biologic formulations are being improved, especially for long-term ailments like arthritis. To meet rising demand and speed up R&D pipelines, AbbVie, for instance, increased production of novel biologic therapies and Humira biosimilars in 2024 at its biologics manufacturing facility in Worcester, Massachusetts. These advancements show how the market is moving toward global scalability, precision therapies, and innovation.
How are Single-Use Bioreactors Revolutionizing Biologics Manufacturing?
One of the biggest technological developments transforming the biologics market outlook is the quick development and sophistication of single-use bioreactor (SUB) systems, which are revolutionizing biologics production in facilities all over the world. To produce recombinant proteins, vaccines, and monoclonal antibodies, for example, WuXi Biologics expanded its capacity from 8,000 L to 23,000 L in June 2024 by installing three 5,000 L single-use bioreactors at its Hangzhou facility.
Market snapshot - 2026-2033
Global Market Size
USD 511.3 billion
Largest Segment
Microbial
Fastest Growth
Mammalian
Growth Rate
11.0% CAGR
To get more insights on this market click here to Request a Free Sample Report
The global biologics market is segmented into source, product, manufacturing, distribution channel, and region. By source, the market is bifurcated into microbial and mammalian. Depending on product, it is categorized into monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAI, & molecular therapy, and cell-based therapies. According to manufacturing, the market is divided into outsources and in-house. As per distribution channel, it is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
What Makes Microbial Platforms the Backbone of Biologics Manufacturing?
As per the 2024 biologics market analysis, the microbial sector led the market because of its cost-effectiveness and efficiency in manufacturing a variety of medications. E. Coli and yeast continue to be the most widely used microbial expression systems. For example, Biocon secured the top spot in the biologics manufacturing market in March 2024 by introducing a biosimilar insulin glargine made by fermentation of E. coli, improving accessibility in developing nations.
The mammalian segment is anticipated to expand at the quickest rate because of its capacity to generate intricate, glycosylated proteins. These technologies are used to produce products such as recombinant insulin, platelet-derived growth factor, and recombinant interferon. In order to satisfy the growing need for novel therapeutic proteins, Lonza also extended its CHO-based mammalian cell facilities in Switzerland in 2025.
How are Monoclonal Antibodies Revolutionizing Targeted Therapy?
As per the 2024 biologics market forecast, in terms of revenue share, the monoclonal antibodies (mAb) segment led the market. They are essential in the treatment of infectious diseases, autoimmune disorders, and cancer because they can precisely target diseased cells without harming healthy tissues. Demand across respiratory care categories increased in March 2024, for instance, when AstraZeneca's Tezspire, a monoclonal antibody used to treat severe asthma, received broader global regulatory approval.
The vaccines category is anticipated to have the highest biologics market share because preventing infectious diseases is becoming more important worldwide. As a routine immunization and pandemic preparedness measure, preventative vaccinations are still becoming more popular. Moderna announced in 2025 that it was expanding its mRNA vaccine pipeline to cover avian influenza and respiratory syncytial virus (RSV), demonstrating increased investment and innovation in the vaccine space.
To get detailed segments analysis, Request a Free Sample Report
Why does North America Continue to Dominate the Biologics Market?
As per the biologics market regional analysis, North America remains the market leader because of its strong R&D, high prevalence of chronic conditions, and advantageous regulatory environments. Big players invest a lot of money in cutting-edge treatments like gene therapies and monoclonal antibodies. Market expansion has been further accelerated by strategic alliances and FDA approvals, particularly in the areas of autoimmune and oncology treatments. Faster clinical trials and commercialization pathways are made possible by the region's sophisticated infrastructure.
U.S. Biologics Market
The U.S. biologics market is the largest across North America because of its early adoption of innovative treatments, favorable reimbursement policies, and significant investment in biotechnology discovery. The FDA authorized numerous new biologics, primarily for cancer and rare diseases. The biologics market outlook through 2025 is supported by the presence of significant players like Amgen, AbbVie, and Pfizer as well as an expanding pipeline of biosimilars that keeps improving patient outcomes and expanding therapeutic diversity.
Canada Biologics Market
Federal investments in biomanufacturing and healthcare innovation have contributed to the steady growth of Canada's biologics sector. By simplifying review procedures, Health Canada accelerated access to innovative biologic drugs in 2024. Approvals of biosimilars increased nationwide as well, especially for rheumatoid arthritis and cancer. Canada is becoming a new hub for biologics research and development in North America because of partnerships between academic institutions and biotech companies that are increasing research capacity.
What makes Asia-Pacific a Lucrative Market for Biologic Therapies?
The Asia-Pacific biologics industry is expanding quickly due to a number of factors, including the prevalence of chronic illnesses, increased access to healthcare, and significant government investment in biotechnology. Clinical research and domestic manufacturing are expanding in nations like China and India. Several biopharma companies in Asia-Pacific reached the stage of international clinical trials. The primary factors impacting the biological market in the region are increased international collaboration, favorable pricing policies, and growing awareness.
China Biologics Market
Strong government support, rising middle-class healthcare spending, and the growth of domestic biotech skills are some of the factors driving China's biologics market. The National Medical Products Administration (NMPA) modified its rules in 2025 to facilitate expedited approvals. Competitive biologics for autoimmune disorders and cancer are still being introduced by companies such as Innovent and BeiGene. China's growing influence in the global market is a result of its dual roles as a producer and consumer of biologics.
India Biologics Market
India's biologics market is expanding due to a large patient base, affordable manufacturing, and increased production of biosimilars. India broadened its Biotech Innovation Policy in 2024, drawing in international capital and public-private alliances. Biosimilars are being exported to regulated markets by domestic companies such as Biocon. Government-led healthcare programs and the rise in chronic illnesses like diabetes and cancer in both urban and rural healthcare segments are also driving the need for biologics.
How is Europe Supporting Biologics Through Regulation and Innovation?
Europe is a biologics powerhouse due to its sophisticated healthcare system and large government investment in life sciences research. The European Medicines Agency (EMA) expedited approval processes, particularly for oncology-related biologics and orphan medications. To increase accessibility and cost-effectiveness, leading countries like Germany, France, and the UK are encouraging the use of biosimilars and supporting biomanufacturing hubs. Partnerships across borders facilitate further market expansion.
UK Biologics Market
Strong regulatory leadership, such as the MHRA's flexible approval processes, supports the UK biologics industry. In 2025, university hospitals conducted more clinical trials, and the government expanded funding for gene and cell therapies. Collaborations like the NHS-AstraZeneca partnership are speeding up the rollout of biologic medications. Biologics research and marketing innovation is being supported both domestically and internationally by the UK's post-Brexit life sciences strategy.
France Biologics Market
Strategic government initiatives like the "France 2030" investment strategy, which gives biotech and pharmaceutical innovation top priority, are helping the nation's biologics industry grow. The EU and the nation provided funding to French companies in 2024 so they could develop novel biologics. Biologic medications are increasingly being used to treat inflammatory diseases and cancer. Clinical research and public access to innovative biologics are fueled by favorable reimbursement laws and the presence of large corporations such as Sanofi.
Germany Biologics Market
When it comes to the creation, production, and uptake of biologics in Europe, Germany is setting the standard. Rapid clinical translation of biologics is made possible by Germany's robust academic-industry ties, extensive public health insurance coverage, and well-developed healthcare system. Biologics that target rare diseases and immunotherapy witnessed significant uptake. Due to investments in biopharmaceutical infrastructure and well-defined laws, the country continues to be a leader in the discovery and production of monoclonal antibodies and biosimilars.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Biologics Market Drivers
Increasing Prevalence of Chronic Illness
Technological Developments in Biomanufacturing
Biologics Market Restraints
High Development and Production Expenses
Strict Rules and Regulations
Request Free Customization of this report to help us to meet your business objectives.
Well-established companies dominate the biologics market and maintain their competitiveness through regional expansions, acquisitions, and the introduction of biosimilars. To expand its rare disease portfolio, Roche purchased a mid-stage immunotherapy company in January 2025. In contrast, Amgen introduced affordable biosimilars to compete in Asia and Europe. AI and machine learning are also being used by companies such as Pfizer to improve clinical trials, speed up discovery, and lower attrition rates, all of which promote increased innovation and operational effectiveness
Top Player’s Company Profile
Recent Developments in Biologics Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the biologics market has witnessed exceptional resilience and growth due to the strong emphasis on emerging factors such as rising rates of chronic diseases, increased demand for personalized medicines and advances in technology and manufacturing. The advancements in AI-enabled drug development, biosimilars and personalized biologics are changing the mindset for companies regarding therapy design and delivery to the market. However, barriers do exist for young companies and developing countries, including complicated regulations and rising manufacturing costs. Various competitive strategies such as partnerships, licensing, mergers and acquisitions will continue to shape the global biologics landscape. Biologics will predict to have a gradual emergence to mainstream medicine in the next decade, representing a significant change in the treatment paradigm for auto-immune disease, cancer and infectious disease, driven by increased governmental investment, enhanced research and development through digitization and changing patient needs.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 567.54 Billion |
| Market size value in 2033 | USD 1451.79 Billion |
| Growth Rate | 11% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biologics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biologics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Biologics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
